title: Interpretation of patient-reported outcomes.
abstract: A patient-reported outcome is any report on the status of a patient's health condition that comes directly from the patient. Clear and meaningful interpretation of patient-reported outcome scores are fundamental to their use as they can be valuable in designing studies, evaluating interventions, educating consumers, and informing health policy makers involved with regulatory, reimbursement, and advisory agencies. Interpretation of patient-reported outcome scores, however, is often not well understood because of insufficient data or lack of experience or clinical understanding to draw from. This article provides an update review on two broad approaches--anchor-based and distributed-based--aimed at enhancing the understanding and meaning of patient-reported outcome scores. Anchor-based approaches include percentages based on thresholds, criterion-group interpretation, content-based interpretation, and clinical important difference. Distributed-based approaches include effect size, probability of relative benefit, and responder analysis and cumulative proportions. A third strategy called mediation analysis, which can elucidate a health condition measured by a patient-reported outcome in the context of an intervention's mechanism of action, is also highlighted and illustrated. Mediation analysis in the context of interpretation of patient-reported outcome scores is a relatively new development. The logic and rationale of the three methods are expressed generally. While the three approaches themselves are not new, some applications of them taken from their examples published in the past few years are original and coalesced in this article to add real-life implications of the different methodologies in one integrated report.
authors: Pfizer Inc, Groton, CT, USA joseph.c.cappelleri@pfizer.com.
authors: Joseph C
authors: JC
authors: Cappelleri
authors: Pfizer Inc, Groton, CT, USA.
authors: Andrew G
authors: AG
authors: Bushmakin
mesh_terms: D000700:Analgesics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003627:Data Interpretation, Statistical; D007172:Erectile Dysfunction / Q000188:drug therapy; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy; D006801:Humans; D008268:Macular Degeneration / Q000473:pathology; D008297:Male; D063868:Patient Outcome Assessment; D010879:Piperazines / Q000627:therapeutic use; D000069583:Pregabalin; D011687:Purines / Q000627:therapeutic use; D018434:Sickness Impact Profile; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D064804:Urological Agents / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000700:Analgesics; D010879:Piperazines; D011687:Purines; D013449:Sulfonamides; D064804:Urological Agents; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D000068677:Sildenafil Citrate
keywords: Patient-reported outcome; anchor-based approach; distribution-based approach; interpretation; mediation analysis